"1210-7832" . "N, V" . "\u010Cesk\u00E1 gynekologie" . . . . . "Zahr\u00E1dkov\u00E1, J." . "2" . "RIV/00064165:_____/10:7230!RIV11-MZ0-00064165" . . "Time of life in estrogen deficiency is continuously prolonged by aging of population. Acute climacteric sysndrome attached about 75% of women after menopause. Level and lenth of problems are individual. Prolonged estrogen deficit is connected with uregenital atrophy, postmenopausal osteoporosis and atherosclerosis. Reccomendation is based on evidence-based datas which show that hormonal therapy in peri and postmenopausal women under 60 year of life could be safety and efficacy."@en . "Koliba, P." . "Jen\u00ED\u010Dek, J." . "[E1335C5F66AB]" . "Doporu\u010Den\u00ED pro hormon\u00E1ln\u00ED substitu\u010Dn\u00ED terapii v postmenopauze." . "Don\u00E1t, J." . "255091" . "CZ - \u010Cesk\u00E1 republika" . "6"^^ . . . . "Recommendation for hormone replacement therapy in postmenopause."@en . "RIV/00064165:_____/10:7230" . "Fait, Tom\u00E1\u0161" . . . "Doporu\u010Den\u00ED pro hormon\u00E1ln\u00ED substitu\u010Dn\u00ED terapii v postmenopauze."@cs . . "Burdov\u00E1, M." . "Recommendation; hormone replacement therapy; postmenopause"@en . "Trval\u00E9 st\u00E1rnut\u00ED populace je spojeno p\u0159i zachovan\u00E9 dob\u011B menopauzy s prodlu\u017Eov\u00E1n\u00EDm doby, kdy \u017Eena \u017Eije ve stavu estrogenn\u00EDho deficitu. Akutn\u00ED pot\u00ED\u017Ee z hormon\u00E1ln\u00ED dysbalance prov\u00E1zej\u00ED vyhasnut\u00ED ovari\u00E1ln\u00ED funkce u p\u0159ibli\u017En\u011B 75% \u017Een. M\u00EDra obt\u00ED\u017E\u00ED a d\u00E9lka jejich p\u0159etrv\u00E1v\u00E1n\u00ED jsou individu\u00E1ln\u00ED. Dlouhodob\u00FD estrogenn\u00ED deficit vede k rozvoji urogenit\u00E1ln\u00ED atrofie, postmenopauz\u00E1ln\u00ED osteopor\u00F3zy a ateroskler\u00F3zy. Doporu\u010Den\u00ED k pod\u00E1v\u00E1n\u00ED hormon\u00E1ln\u00ED terapie (HT), kter\u00E9 je p\u0159edkl\u00E1d\u00E1no v tomto dokumentu, je zalo\u017Eeno na sou\u010Dasn\u00FDch d\u016Fkazech, \u017Ee HT podan\u00E1 symptomatick\u00E9 peri- nebo postmenopauz\u00E1ln\u00ED zdrav\u00E9 \u017Een\u011B mlad\u0161\u00ED 60 let m\u016F\u017Ee b\u00FDt \u00FA\u010Deln\u00E1 a bezpe\u010Dn\u00E1."@cs . "Recommendation for hormone replacement therapy in postmenopause."@en . "1"^^ . . "Doporu\u010Den\u00ED pro hormon\u00E1ln\u00ED substitu\u010Dn\u00ED terapii v postmenopauze."@cs . . "2"^^ . . "75" . . "Doporu\u010Den\u00ED pro hormon\u00E1ln\u00ED substitu\u010Dn\u00ED terapii v postmenopauze." . "Trval\u00E9 st\u00E1rnut\u00ED populace je spojeno p\u0159i zachovan\u00E9 dob\u011B menopauzy s prodlu\u017Eov\u00E1n\u00EDm doby, kdy \u017Eena \u017Eije ve stavu estrogenn\u00EDho deficitu. Akutn\u00ED pot\u00ED\u017Ee z hormon\u00E1ln\u00ED dysbalance prov\u00E1zej\u00ED vyhasnut\u00ED ovari\u00E1ln\u00ED funkce u p\u0159ibli\u017En\u011B 75% \u017Een. M\u00EDra obt\u00ED\u017E\u00ED a d\u00E9lka jejich p\u0159etrv\u00E1v\u00E1n\u00ED jsou individu\u00E1ln\u00ED. Dlouhodob\u00FD estrogenn\u00ED deficit vede k rozvoji urogenit\u00E1ln\u00ED atrofie, postmenopauz\u00E1ln\u00ED osteopor\u00F3zy a ateroskler\u00F3zy. Doporu\u010Den\u00ED k pod\u00E1v\u00E1n\u00ED hormon\u00E1ln\u00ED terapie (HT), kter\u00E9 je p\u0159edkl\u00E1d\u00E1no v tomto dokumentu, je zalo\u017Eeno na sou\u010Dasn\u00FDch d\u016Fkazech, \u017Ee HT podan\u00E1 symptomatick\u00E9 peri- nebo postmenopauz\u00E1ln\u00ED zdrav\u00E9 \u017Een\u011B mlad\u0161\u00ED 60 let m\u016F\u017Ee b\u00FDt \u00FA\u010Deln\u00E1 a bezpe\u010Dn\u00E1." .